Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5,4 NOK | +0,75% | -3,23% | +11,11% |
10/04 | Lytix Biopharma haalt tot 55 miljoen Noorse kronen op via aandelenuitgifte | MT |
29/02 | Transcript : Lytix Biopharma AS, Q4 2023 Earnings Call, Feb 29, 2024 |
Omzet 2023 | - | Omzet 2024 * | 6,3 mln. 574K 0 | Marktkapitalisatie | 216 mln. 19,71 mln. 0 |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -87 -7,92 - | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | - |
Nettoliquiditeiten 2023 * | 49,6 mln. 4,52 mln. 0 | Nettoliquiditeiten 2024 * | 61,8 mln. 5,63 mln. 0 | EV/omzet 2024 * | 24,5 x |
K/w-verhouding 2023 * |
-
| K/w-verhouding 2024 * |
-
| Werknemers | 8 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 53,93% |
Recentste transcriptie over Lytix Biopharma
1 dag | +0,75% | ||
1 week | -3,23% | ||
Lopende maand | -11,48% | ||
1 maand | -18,18% | ||
3 maanden | -20,59% | ||
6 maanden | -18,18% | ||
Lopend jaar | +11,11% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Øystein Rekdal
CEO | Chief Executive Officer | - | 01-01-03 |
Gjest Breistein
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 01-01-08 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Kjetil Hestdal
BRD | Director/Board Member | 64 | 07-06-21 |
Director/Board Member | 66 | 07-06-21 | |
Jayson M. Rieger
BRD | Director/Board Member | 48 | 07-06-21 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
24-04-24 | 5,4 | +0,75% | 14 221 |
23-04-24 | 5,36 | -3,60% | 85 174 |
22-04-24 | 5,56 | +4,91% | 12 663 |
19-04-24 | 5,3 | -3,64% | 7 100 |
18-04-24 | 5,5 | -1,43% | 15 445 |
Real Time Oslo Bors, 24 april 2024 om 16:45 uur
Meer koersenChiffre d''affaires - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,11% | 19,67 mln. | |
+4,09% | 43,84 mld. | |
+47,81% | 41,25 mld. | |
+9,45% | 41,68 mld. | |
-10,92% | 27,04 mld. | |
+9,32% | 25,53 mld. | |
-24,87% | 18,18 mld. | |
+29,70% | 12,29 mld. | |
+1,28% | 12,29 mld. | |
+7,78% | 11,15 mld. |